scholarly journals Therapy Algorithm for Portal Vein Thrombosis in Liver Cirrhosis: The Internist's Point of View

2014 ◽  
Vol 30 (6) ◽  
pp. 8-8 ◽  
Author(s):  
Martin Rössle ◽  
Birke Bausch ◽  
Christoph Klinger
Keyword(s):  
Liver Cirrhosis ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Point Of View ◽  
Therapy Algorithm ◽  
Vein Thrombosis

Antiphospholipid Antibodies and Antiphospholipid Syndrome: Role in Portal Vein Thrombosis in Patients With and Without Liver Cirrhosis

2010 ◽  
Vol 17 (4) ◽  
pp. 367-370 ◽  
Author(s):  
Lucio Amitrano ◽  
Paul R. J. Ames ◽  
Maria Anna Guardascione ◽  
Luis R. Lopez ◽  
Antonella Menchise ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Vein Thrombosis

Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis

2018 ◽  
Vol 41 (10) ◽  
pp. 611-617
Author(s):  
Tomas Artaza ◽  
Miriam Lopes ◽  
Marta Romero ◽  
Ana-Zaida Gómez ◽  
Gema de la Cruz ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Efficacy And Safety ◽  
Vein Thrombosis

scholarly journals Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Satoshi Nakayama ◽  
Naoya Murashima
Keyword(s):  
Liver Cirrhosis ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Antithrombin Iii ◽  
Anticoagulation Therapy ◽  
Major Complication ◽  
Recombinant Form ◽  
Soluble Thrombomodulin ◽  
Vein Thrombosis ◽  
Coagulation Therapy

Portal vein thrombosis is a major complication associated with liver cirrhosis. In cirrhotic patients, a decrease in procoagulant and anticoagulant factors and an unstable balance between them is observed, and a relative decrease in the activation of anticoagulant drivers is one of the main causes of portal vein thrombosis (PVT). Herein, we report a case of acute portal thrombosis associated with liver cirrhosis and treated with a recombinant form of soluble thrombomodulin (thrombomodulin alpha, TM-α) in combination with antithrombin III. TM-α was administered in accordance with the dosage and route of administration for disseminated intravascular coagulation therapy and resulted in dissolution of PVT with a gradual decrease in D-dimer levels. No adverse events were observed during the course of treatment. In the future, in addition to conventional anticoagulation therapy using heparin or antivitamin K drugs, novel therapies targeting protein C activation using a recombinant form of soluble thrombomodulin may play an important role in the treatment of acute PVT.

Sign in / Sign up

Export Citation Format

Share Document